Journal of Nuclear Medicine

Papers
(The H4-Index of Journal of Nuclear Medicine is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results172
Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard151
A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies130
Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients122
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer101
FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?98
Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study90
68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT88
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of88
Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study83
68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership80
Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial78
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging77
Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer76
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics76
Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome74
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy70
Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients70
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy69
First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients67
68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial67
Imaging of Pheochromocytoma and Paraganglioma65
SNMMI Procedure Standard/EANM Practice Guideline on Pediatric18F-FDG PET/CT for Oncology 1.063
Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis63
The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review61
Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients56
First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy53
Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary P53
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling52
Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome51
The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals50
Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer50
First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC49
Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?48
Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review48
Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development47
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE47
Imaging of Synaptic Density in Neurodegenerative Disorders47
Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT46
Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE Guidelines)46
PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer45
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody44
COVID-19 mRNA Vaccination: Age and Immune Status and Its Association with Axillary Lymph Node PET/CT Uptake43
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns43
Direct Comparison of the Tau PET Tracers18F-Flortaucipir and18F-MK-6240 in Human Subjects43
0.53641510009766